As the flurry of executive orders continues to flow from the White House, leaving in its wake chaos and confusion across the ...

In response to the news of reported layoffs at the U.S. FDA over the weekend, Advanced Medical Association president and CEO ...

Once high-flying Bluebird Bio Inc. has found a way out of its financial squeeze, as funds managed by global investment firms ...

Researchers from Columbia University Irving Medical Center and collaborators applied unbiased scRNA-seq to study Lepr ...

Gene therapy specialist Meiragtx Holdings plc is heading for its first marketing approval following the successful treatment ...

Roche Holding AG revealed plans to launch its sequencing by expansion technology next year, raising the possibility that ...

Using ALK+ lung cancer patient-derived cell lines, researchers have performed phosphoproteomic screening and identified ...

Approxima Srl raised €7.3 million (US$7.65 million) in the first close of its series A financing round for its tricuspid valve repair system which is based on reshaping the right ventricle.

A paper published in The Lancet showed that four out of four young children with Leber congenital amaurosis 4 retinal dystrophy due to a genetic deficiency of Aryl-hydrocarbon-interacting protein-like ...

EG 427 SAS has closed a €27 million (US$28.3 million) series B round, which will fund it to completion of the first clinical ...

The U.S. FDA approved 12 drugs in January, falling below the 2024 monthly average of 19. Only three new molecular entities received approval, trailing the yearly average of just over four per month.

Photys Therapeutics Inc. has signed a license agreement with Hangzhou Polymed Biopharmaceuticals Inc. for HPB-143, a phase I-ready IRAK-4 degrader. IRAK-4 degradation offers potential to treat various ...